Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Blood (2025) 146 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2025-2838

Published: 2025

Journal Articles

Pediatric-inspired regimens for ALL are not associated with improved overall survival in US hispanic adult patients

Alexander Krule, Ryan Sun, Ahmad Nassar, Nepheli Raptis, Samer Yassin, Daniel McLoughlin, Fabiola Marie Moreno Echevarria, Shira Dinner, Madelyn Burkart, Irum Khan, John Quigley

Blood (2025) 146 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2025-2731

Published: 2025

Journal Articles

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Blood (2025) 146 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2025-1614

Published: 2025

Journal Articles

Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials

Blood blood.2025030741.

https://doi.org/10.1182/blood.2025030741

Published: 2025

Includes: Supplemental data

Journal Articles

It's All in the Granules: Capnocytophaga Vs. APL

Sean Ormond, Alyssa Simon, Dustin Norton, Madelyn Burkart, Sarada Krishnamurthy

Blood (2024) 144 (Supplement 1): 5386.

https://doi.org/10.1182/blood-2024-199261

Published: 2024

Journal Articles

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2024-194857

Published: 2024

Journal Articles

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Blood (2024) 144 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2024-197898

Published: 2024

Journal Articles

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Justin Grenet, Neela Easwar, Akriti G. Jain, Madelyn Burkart, Xiaoyue Ma, Paul Christos, Ellen K. Ritchie, Michael Samuel, Justin D. Kaner, Jonathan Canaani, Aaron D. Goldberg, Shira N. Dinner, Kendra L. Sweet, Gail J. Roboz, Pinkal Desai

Blood (2024) 144 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2024-206340

Published: 2024

Journal Articles

The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia

Abdur Rahman Jabir, Anna Lisa Ciarrocca, Nathaniel O'Connell, Kelly Needles, Timothy S Pardee, Rupali Bhave, Leslie R Ellis, Matthew J. Wieduwilt, Bayard L Powell, Madelyn Burkart

Blood (2024) 144 (Supplement 1): 2858.

https://doi.org/10.1182/blood-2024-208295

Published: 2024

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Blood (2023) 142 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2023-174790

Published: 2023

Journal Articles

Individual-Level Social Determinants of Health (SDOH) Measures and Treatment Complications in Acute Leukemia

Blood (2023) 142 (Supplement 1): 374.

https://doi.org/10.1182/blood-2023-189024

Published: 2023

Journal Articles

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2023-188328

Published: 2023

Journal Articles

The Impact of Air Pollutants on a Chicagoland Cohort of Patients with Acute Myeloid Leukemia

Andrew Palmer, Garth Rauscher, Ivy Abraham, Madelyn Burkart, Ami Dave, Nepheli Raptis, Ahmed Aleem, Vedavyas Gannamani, Amani Erra, Sarah Monick, Carlos Galvez, Melissa L. Larson, Maryam Zia, Stephanie B. Tsai, Jessica K. Altman, Wendy Stock, Irum Khan, Anand Ashwin Patel

Blood (2023) 142 (Supplement 1): 3806.

https://doi.org/10.1182/blood-2023-178265

Published: 2023

Journal Articles

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 6058–6060.

https://doi.org/10.1182/blood-2022-163795

Published: 2022

Journal Articles

Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis

Megan Melody, Madelyn Burkart, Marcelo Villa, Fenlu Zhu, Jane N. Winter, Reem Karmali, Adam Yuh Lin, Leo I. Gordon, Kehinde Adekola, Jonathan Moreira, Seema Singhal, Jayesh Mehta

Blood (2022) 140 (Supplement 1): 4703–4704.

https://doi.org/10.1182/blood-2022-167872

Published: 2022

Journal Articles

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 1435–1437.

https://doi.org/10.1182/blood-2022-167731

Published: 2022

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Anand Ashwin Patel, James J. Yoon, Hannah Johnston, Evan C. Chen, Madelyn Burkart, Timothy Seijung Oh, Sunil G. Iyer, Ellen Madarang, Iyana Gross, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Rory Michael Shallis, Guru Subramanian Guru Murthy, Vikas Gupta, Kristen M. Pettit, John Cursio, Olatoyosi Odenike

Blood (2022) 140 (Supplement 1): 6860–6862.

https://doi.org/10.1182/blood-2022-157603

Published: 2022

Journal Articles

Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

Blood (2022) 139 (14): 2212–2226.

https://doi.org/10.1182/blood.2021012830

Published: 2022

Includes: Supplemental data

Journal Articles

Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 32.

https://doi.org/10.1182/blood-2021-145947

Published: 2021

Journal Articles

Outcomes and Predictors of Relapse with Use of Hypomethylating Agents in Combination with Venetoclax Prior to Allogeneic Transplant in Acute Myeloid Leukemia

Imran Nizamuddin, Timothy Seijung Oh, Yazan Numan, Max Farber Kelsten, Madelyn Burkart, Olga Frankfurt, Carlos E. Vigil, Yasmin Abaza, Jessica K. Altman, Shira Dinner

Blood (2021) 138 (Supplement 1): 2327.

https://doi.org/10.1182/blood-2021-150815

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Pediatric-inspired regimens for ALL are not associated with improved overall survival in US hispanic adult patients

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials

It's All in the Granules: Capnocytophaga Vs. APL

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Individual-Level Social Determinants of Health (SDOH) Measures and Treatment Complications in Acute Leukemia

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

The Impact of Air Pollutants on a Chicagoland Cohort of Patients with Acute Myeloid Leukemia

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Structural racism is a mediator of disparities in acute myeloid leukemia outcomes

Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Outcomes and Predictors of Relapse with Use of Hypomethylating Agents in Combination with Venetoclax Prior to Allogeneic Transplant in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only